241 related articles for article (PubMed ID: 25363835)
21. The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia.
Beinat C; Banister SD; Herrera M; Law V; Kassiou M
CNS Drugs; 2015 Jul; 29(7):529-42. PubMed ID: 26242477
[TBL] [Abstract][Full Text] [Related]
22. Radiochemical synthesis and in vivo evaluation of [18F]AZ11637326: an agonist probe for the α7 nicotinic acetylcholine receptor.
Ravert HT; Dorff P; Foss CA; Mease RC; Fan H; Holmquist CR; Phillips E; McCarthy DJ; Heys JR; Holt DP; Wang Y; Endres CJ; Dannals RF; Pomper MG
Nucl Med Biol; 2013 Aug; 40(6):731-9. PubMed ID: 23680470
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and safety profile of ispronicline (TC-1734), a new brain nicotinic receptor partial agonist, in young healthy male volunteers.
Dunbar G; Demazières A; Monreal A; Cisterni C; Metzger D; Kuchibhatla R; Luthringer R
J Clin Pharmacol; 2006 Jul; 46(7):715-26. PubMed ID: 16809797
[TBL] [Abstract][Full Text] [Related]
24. Single- and multiple-dose pharmacokinetics, safety, and tolerability of the selective alpha7 neuronal nicotinic receptor agonist, ABT-107, in healthy human volunteers.
Othman AA; Lenz RA; Zhang J; Li J; Awni WM; Dutta S
J Clin Pharmacol; 2011 Apr; 51(4):512-26. PubMed ID: 20495134
[TBL] [Abstract][Full Text] [Related]
25. Genetic deletion of the adenosine A(2A) receptor prevents nicotine-induced upregulation of α7, but not α4β2* nicotinic acetylcholine receptor binding in the brain.
Metaxas A; Al-Hasani R; Farshim P; Tubby K; Berwick A; Ledent C; Hourani S; Kitchen I; Bailey A
Neuropharmacology; 2013 Aug; 71():228-36. PubMed ID: 23583933
[TBL] [Abstract][Full Text] [Related]
26. Identification and in vitro pharmacological characterization of a novel and selective α7 nicotinic acetylcholine receptor agonist, Br-IQ17B.
Tang JS; Xie BX; Bian XL; Xue Y; Wei NN; Zhou JH; Hao YC; Li G; Zhang LR; Wang KW
Acta Pharmacol Sin; 2015 Jul; 36(7):800-12. PubMed ID: 25948478
[TBL] [Abstract][Full Text] [Related]
27. Hydroxy metabolites of the Alzheimer's drug candidate 3-[(2,4-dimethoxy)benzylidene]-anabaseine dihydrochloride (GTS-21): their molecular properties, interactions with brain nicotinic receptors, and brain penetration.
Kem WR; Mahnir VM; Prokai L; Papke RL; Cao X; LeFrancois S; Wildeboer K; Prokai-Tatrai K; Porter-Papke J; Soti F
Mol Pharmacol; 2004 Jan; 65(1):56-67. PubMed ID: 14722237
[TBL] [Abstract][Full Text] [Related]
28. Discovery of a novel alpha-7 nicotinic acetylcholine receptor agonist series and characterization of the potent, selective, and orally efficacious agonist 5-(4-acetyl[1,4]diazepan-1-yl)pentanoic acid [5-(4-methoxyphenyl)-1H-pyrazol-3-yl] amide (SEN15924, WAY-361789).
Zanaletti R; Bettinetti L; Castaldo C; Cocconcelli G; Comery T; Dunlop J; Gaviraghi G; Ghiron C; Haydar SN; Jow F; Maccari L; Micco I; Nencini A; Scali C; Turlizzi E; Valacchi M
J Med Chem; 2012 May; 55(10):4806-23. PubMed ID: 22468936
[TBL] [Abstract][Full Text] [Related]
29. Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders.
Roncarati R; Scali C; Comery TA; Grauer SM; Aschmi S; Bothmann H; Jow B; Kowal D; Gianfriddo M; Kelley C; Zanelli U; Ghiron C; Haydar S; Dunlop J; Terstappen GC
J Pharmacol Exp Ther; 2009 May; 329(2):459-68. PubMed ID: 19223665
[TBL] [Abstract][Full Text] [Related]
30. RG3487, a novel nicotinic α7 receptor partial agonist, improves cognition and sensorimotor gating in rodents.
Wallace TL; Callahan PM; Tehim A; Bertrand D; Tombaugh G; Wang S; Xie W; Rowe WB; Ong V; Graham E; Terry AV; Rodefer JS; Herbert B; Murray M; Porter R; Santarelli L; Lowe DA
J Pharmacol Exp Ther; 2011 Jan; 336(1):242-53. PubMed ID: 20959364
[TBL] [Abstract][Full Text] [Related]
31. The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21).
Kem WR
Behav Brain Res; 2000 Aug; 113(1-2):169-81. PubMed ID: 10942043
[TBL] [Abstract][Full Text] [Related]
32. In vitro pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107.
Malysz J; Anderson DJ; Grønlien JH; Ji J; Bunnelle WH; Håkerud M; Thorin-Hagene K; Ween H; Helfrich R; Hu M; Gubbins E; Gopalakrishnan S; Puttfarcken PS; Briggs CA; Li J; Meyer MD; Dyhring T; Ahring PK; Nielsen EØ; Peters D; Timmermann DB; Gopalakrishnan M
J Pharmacol Exp Ther; 2010 Sep; 334(3):863-74. PubMed ID: 20504915
[TBL] [Abstract][Full Text] [Related]
33. TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia.
Hauser TA; Kucinski A; Jordan KG; Gatto GJ; Wersinger SR; Hesse RA; Stachowiak EK; Stachowiak MK; Papke RL; Lippiello PM; Bencherif M
Biochem Pharmacol; 2009 Oct; 78(7):803-12. PubMed ID: 19482012
[TBL] [Abstract][Full Text] [Related]
34. SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile.
Biton B; Bergis OE; Galli F; Nedelec A; Lochead AW; Jegham S; Godet D; Lanneau C; Santamaria R; Chesney F; Léonardon J; Granger P; Debono MW; Bohme GA; Sgard F; Besnard F; Graham D; Coste A; Oblin A; Curet O; Vigé X; Voltz C; Rouquier L; Souilhac J; Santucci V; Gueudet C; Françon D; Steinberg R; Griebel G; Oury-Donat F; George P; Avenet P; Scatton B
Neuropsychopharmacology; 2007 Jan; 32(1):1-16. PubMed ID: 17019409
[TBL] [Abstract][Full Text] [Related]
35. alpha7 Nicotinic receptor gene delivery into mouse hippocampal neurons leads to functional receptor expression, improved spatial memory-related performance, and tau hyperphosphorylation.
Ren K; Thinschmidt J; Liu J; Ai L; Papke RL; King MA; Hughes JA; Meyer EM
Neuroscience; 2007 Mar; 145(1):314-22. PubMed ID: 17218065
[TBL] [Abstract][Full Text] [Related]
36. Augmentation of cognitive function by NS9283, a stoichiometry-dependent positive allosteric modulator of α2- and α4-containing nicotinic acetylcholine receptors.
Timmermann DB; Sandager-Nielsen K; Dyhring T; Smith M; Jacobsen AM; Nielsen EØ; Grunnet M; Christensen JK; Peters D; Kohlhaas K; Olsen GM; Ahring PK
Br J Pharmacol; 2012 Sep; 167(1):164-82. PubMed ID: 22506660
[TBL] [Abstract][Full Text] [Related]
37. 3-Furan-2-yl-N-p-tolyl-acrylamide, a positive allosteric modulator of the α7 nicotinic receptor, reverses schizophrenia-like cognitive and social deficits in rats.
Potasiewicz A; Hołuj M; Kos T; Popik P; Arias HR; Nikiforuk A
Neuropharmacology; 2017 Feb; 113(Pt A):188-197. PubMed ID: 27717880
[TBL] [Abstract][Full Text] [Related]
38. Ventral hippocampal alpha7 and alpha4beta2 nicotinic receptor blockade and clozapine effects on memory in female rats.
Pocivavsek A; Icenogle L; Levin ED
Psychopharmacology (Berl); 2006 Nov; 188(4):597-604. PubMed ID: 16715255
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis and biological evaluation of 1,4-Diazobicylco[3.2.2]nonane derivatives as α7-Nicotinic acetylcholine receptor PET/CT imaging agents and agonists for Alzheimer's disease.
Wang S; Fang Y; Wang H; Gao H; Jiang G; Liu J; Xue Q; Qi Y; Cao M; Qiang B; Zhang H
Eur J Med Chem; 2018 Nov; 159():255-266. PubMed ID: 30296684
[TBL] [Abstract][Full Text] [Related]
40. The selective nicotinic acetylcholine receptor alpha7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain.
Feuerbach D; Lingenhoehl K; Olpe HR; Vassout A; Gentsch C; Chaperon F; Nozulak J; Enz A; Bilbe G; McAllister K; Hoyer D
Neuropharmacology; 2009 Jan; 56(1):254-63. PubMed ID: 18793655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
